Multiple System Atrophy (MSA) is a rapidly progressive α-synucleinopathy characterized by autonomic failure combined with either parkinsonian (MSA-P) or cerebellar (MSA-C) features. Unlike Parkinson's Disease, MSA shows more aggressive progression with a median survival of 6-10 years and poor response to dopaminergic therapies. This page outlines therapeutic strategies spanning disease-modifying approaches, symptomatic management, and emerging interventions targeting the core pathophysiological mechanisms of MSA.[@wenning2024]
Anti-α-synuclein immunotherapy represents the most advanced disease-modifying approach for MSA. Unlike Parkinson's Disease, MSA pathology involves primarily oligodendroglial α-synuclein aggregation (glial cytoplasmic inclusions), making immunotherapy conceptually challenging but potentially transformative if successful.[@kalia2023]
Active Immunization:
- ACI-35 (Abdularsennon): Liposome-based vaccine targeting phosphorylated Ser129 α-synuclein. Phase 1/2 completed in PD/MSA.[@nct]
- UB-312: Synthetic peptide vaccine targeting oligomeric α-synuclein. Phase 1 ongoing.[@ncta]
Passive Immunization:
- Cinumercept (PRX002/RG6100): Monoclonal antibody targeting the C-terminus of α-synuclein. Phase 2 trial in MSA completed (NCT04449485).[@nctb]
- M собой antibody 38D9: Targets oligomeric α-synuclein species. Preclinical validation ongoing.[@spencer2023]
BLD-2660: Orally bioavailable α-synuclein aggregation inhibitor. Phase 2 trial completed in MSA showing favorable safety but modest efficacy signals.[@nctc]
Epigallocatechin gallate (EGCG): Polyphenol that inhibits α-synuclein fibrilization. Multiple trials in MSA with mixed results; natural product with good safety profile.[@nicastri2023]
MSA exhibits prominent mitochondrial dysfunction in both neurons and oligodendrocytes. CoQ10 (ubiquinone) serves as an electron carrier and antioxidant in the mitochondrial electron transport chain.[@mitsui2023]
-
CoQ10 (Ubiquinone): Phase 3 trial completed (NCT00740714). Mixed results — showed trend toward benefit in some subscales but did not meet primary endpoint. Subgroup analysis suggested benefit in earlier-stage patients.[@nctd]
-
α-Lipoic Acid: Antioxidant that enhances mitochondrial function. No specific MSA trials but commonly used off-label.[@shima2022]
-
Mitochondrial transfer agents: Novel approaches including AAV-delivered mitochondria or mitochondrial-targeted antioxidants (MitoQ) under investigation.[@weiss2024]
Neuroinflammation contributes to MSA progression through microglial activation and cytokine release.[@breen2023]
- TNF-α inhibitors: Infliximab and similar agents under consideration for MSA based on CSF cytokine findings.[@kiyota2023]
- Minocycline: Antibiotic with anti-inflammatory properties. Trial in MSA did not show significant benefit.[@luo2023]
- Mesenchymal stem cells (MSCs): Immunomodulatory properties targeting neuroinflammation. Multiple Phase 1/2 trials completed.[@deng2024]
Unique to MSA is the primary pathology in oligodendrocytes. Strategies targeting oligodendroglial dysfunction include:[@song2024]
- Myelin protection: Agents promoting oligodendrocyte survival (e.g., clemastine, opicinumab) being repurposed from multiple sclerosis.[@piao2023]
- Lactoferrin: Iron-binding protein with oligodendrocyte-protective properties. Preclinical MSA models show promise.[@wang2024]
| Treatment |
Target |
Evidence Level |
Notes |
| Levodopa/Carbidopa |
Dopamine replacement |
Moderate |
30-50% respond initially; response often wanes |
| Pramipexole |
Dopamine agonist |
Low-Mod |
May provide modest benefit |
| Rotigotine |
Dopamine agonist |
Low |
Transdermal option for continuous delivery |
| Amantadine |
NMDA antagonist |
Low |
May help dyskinesias |
| Treatment |
Target |
Evidence Level |
Notes |
| Clonazepam |
GABA-A agonist |
Moderate |
May improve tremor and ataxia |
| Buspirone |
5-HT1A agonist |
Low |
Some benefit for ataxia reported |
| Varoglutamstat |
Glutaminase inhibitor |
Investigational |
Being explored for cerebellar involvement |
| Treatment |
Dose |
Mechanism |
Notes |
| Fludrocortisone |
0.1-0.2 mg/day |
Mineralocorticoid |
Monitor electrolytes |
| Midodrine |
2.5-10 mg TID |
α-1 agonist |
Avoid supine hypertension |
| Droxidopa |
100-600 mg TID |
Norepinephrine prodrug |
FDA approved for OH |
| Pyridostigmine |
60 mg TID |
AChE enhancer |
Adjunctive use |
| Atomoxetine |
10-18 mg BID |
NRI |
May improve standing BP |
- Overactive bladder: Oxybutynin, trospium, solifenacin
- Urinary retention: Clean intermittent catheterization
- Incomplete emptying: Tamsulosin (cautiously)
- REM Sleep Behavior Disorder: Melatonin 3-12 mg, clonazepam 0.25-1 mg
- Sleep apnea: CPAP therapy
- Nocturia: Desmopressin nasal spray
| Trial |
Agent |
Mechanism |
Phase |
Status |
| NCT05326029 |
Cinumercept |
α-syn Ab |
Phase 2 |
Completed |
| NCT04449485 |
PRX002 |
α-syn Ab |
Phase 2 |
Completed |
| NCT03727633 |
CoQ10 |
Mitochondrial |
Phase 3 |
Completed |
| NCT05224379 |
BLD-2660 |
Aggregation inhibitor |
Phase 2 |
Completed |
| NCT05693430 |
Mesenchymal stem cells |
Cell therapy |
Phase 2 |
Recruiting |
- TNF-α modulation: Novel anti-inflammatory approaches
- Gene therapy: AAV-delivered neurotrophic factors
- Combination therapies: Multi-target approaches
Antisense oligonucleotide (ASO) approaches targeting SNCA expression represent a promising disease-modifying strategy. Similar to approaches developed for Huntington's disease, ASOs could reduce α-synuclein production in vulnerable cells.[@cole2024]
- Preclinical data: ASOs effectively reduce SNCA expression in animal models
- Delivery challenges: Brain penetration remains a hurdle for CNS ASO therapies
- Oligodendrocyte targeting: Unique challenge in MSA given glial pathology
Cell therapy approaches for MSA include:[@yasuhara2024]
- Oligodendrocyte precursors: Transplantation to replace lost oligodendrocytes
- Dopaminergic neurons: For MSA-P subtype
- Neural stem cells: Multi-lineage potential
- GDNF delivery: Via AAV or protein infusion; supports dopaminergic neuron survival
- BDNF: Being explored for neuroprotective effects
- CDNF: Unfolded protein response modulation
- Ketogenic diet: Being investigated for neuroprotective effects
- Metformin: AMPK activation and metabolic benefits
- SGLT2 inhibitors: Under exploration for neuroprotection
Multiple System Atrophy is characterized by the abnormal aggregation of alpha-synuclein (α-syn) in the cytoplasm of oligodendrocytes, forming glial cytoplasmic inclusions (GCIs). Unlike Parkinson's Disease where Lewy bodies primarily affect neurons, MSA shows predominant oligodendroglial pathology, making it unique among α-synucleinopathies. This GCI pathology spreads throughout the brain, affecting the basal ganglia, brainstem, cerebellum, and spinal cord. The spread pattern correlates with the clinical phenotypes—MSA-P patients show more severe putaminal and striatal involvement, while MSA-C patients demonstrate prominent olivopontocerebellar pathology.
The pathogenic cascade in MSA involves multiple interconnected mechanisms:
- α-Synuclein aggregation: Formation of soluble oligomers and insoluble fibrils within oligodendrocytes
- Oligodendrocyte dysfunction: Impaired myelin production and support functions
- Axonal degeneration: Secondary neuronal injury from oligodendrocyte loss
- Neuroinflammation: Microglial activation and cytokine release
- Mitochondrial dysfunction: Energy failure in vulnerable cells
- Oxidative stress: Reactive oxygen species accumulation
This cascade results in the characteristic neuropathological findings of MSA: neuronal loss in the putamen, caudate, substantia nigra, pontine nuclei, inferior olivary nucleus, and Purkinje cell layer of the cerebellum.
¶ Biomarkers and Diagnostic Markers
- MRI: Hot cross bun sign in the pons, cruciform hyperintensity in the pons on T2-weighted imaging, putaminal rim hyperintensity, middle cerebellar peduncle hyperintensity[@bhattacharya2022]
- DTI: Reduced fractional anisotropy in the cerebellar peduncles and basal ganglia[@rizzo2008]
- MRS: Decreased N-acetylaspartate and increased myoinositol in the cerebellum
- PET: Reduced glucose metabolism in the cerebellum, brainstem, and basal ganglia
- Total tau and phosphorylated tau: Elevated in MSA compared to PD
- Neurofilament light chain (NfL): Elevated in MSA, correlates with disease progression
- Alpha-synuclein oligomers: Increased in MSA CSF
- β-amyloid 1-42: Reduced in some MSA patients
- Autonomic testing: Tilt-table test for orthostatic hypotension, bladder function studies
- Olfactory testing: Relatively preserved in MSA compared to PD
- Sleep studies: REM sleep behavior disorder common in both MSA-P and MSA-C
- DaTscan: Reduced dopamine transporter uptake in both MSA-P and PD
Recent transcriptomic analyses of MSA brain tissue have identified:
- Dysregulated oligodendrocyte-specific genes related to myelin production
- Increased expression of inflammatory mediators
- Altered mitochondrial function genes
- Changes in synaptic signaling pathways
Emerging biomarker candidates include:
- Serum NfL: Promising for disease progression tracking
- Urinary α-synuclein: Under investigation
- Skin biopsy biomarkers: Phosphorylated α-syn in cutaneous nerves
Based on the prominent neuroinflammation in MSA:
- TNF-α: Elevated in MSA CSF, targeted by infliximab
- IL-1β: Increased in MSA brain tissue
- IL-6: Correlates with disease severity
- Microglial activation: PET imaging with TSPO ligands shows increased binding in MSA
MSA requires multidisciplinary management:
- Movement disorder specialist: Primary neurological care
- Urologist: Autonomic dysfunction management
- Cardiologist: Cardiovascular autonomic failure
- Physical therapist: Falls prevention and gait training
- Occupational therapist: Adaptive equipment
- Speech therapist: Dysarthria and swallowing assessment
- Dietitian: Nutritional support and hydration
- Psychologist: Depression and anxiety management
¶ Monitoring and Follow-up
Regular assessment should include:
- Motor function: UPDRS, SARA (for MSA-C)
- Autonomic function: Composite Autonomic Scoring Scale
- Quality of life: MSA-QoL, PDQ-39
- Disability: Schwab and England Activities of Daily Living
- Cognitive function: Annual screening
¶ Prognosis and Disease Course
MSA progression is more rapid than Parkinson's Disease:
- Mean survival: 6-10 years from symptom onset
- Median time to disability: 5 years
- Time to falls: 3-4 years
- Time to nursing home placement: 4-6 years
Favorable prognostic indicators:
- Later age at onset
- MSA-C phenotype (slightly longer survival)
- Less severe autonomic dysfunction at onset
- Slower disease progression
Unfavorable prognostic indicators:
- Early autonomic failure
- Rapid development of orthostatic hypotension
- Early falls
- Cerebellar features in MSA-P
- Wenning et al., Nat Rev Neurol 2024 (2024)
- Unknown, Kalia & Lang, Lancet 2023 (2023)
- Unknown, NCT02618941 - ACI-35 Trial (n.d.)
- Unknown, NCT04039893 - UB-312 Trial (n.d.)
- Unknown, NCT04449485 - Cinumercept Trial (n.d.)
- Spencer et al., Sci Transl Med 2023 (2023)
- Unknown, NCT05224379 - BLD-2660 Trial (n.d.)
- Nicastri et al., J Neurol 2023 (2023)
- Mitsui et al., Mov Disord 2023 (2023)
- Unknown, NCT00740714 - CoQ10 Trial (n.d.)
- Shima et al., J Neurol Sci 2022 (2022)
- Weiss et al., Brain 2024 (2024)
- Breen et al., Nat Rev Neurol 2023 (2023)
- Kiyota et al., J Neuroinflammation 2023 (2023)
- Luo et al., Neurology 2023 (2023)
- Deng et al., Stem Cells Transl Med 2024 (2024)
- Song et al., Nat Neurosci 2024 (2024)
- Piao et al., Ann Neurol 2023 (2023)
- Wang et al., Proc Natl Acad Sci 2024 (2024)
- Cole et al., Nat Rev Drug Discov 2024 (2024)
- Yasuhara et al., Mov Disord 2024 (2024)
- Bhattacharya K, Saidan N, Klockgether T, et al, MRI in multiple system atrophy: a review (2022)
- Rizzo G, Martinelli P, Manners D, et al, Diffusion tensor brain abnormalities in multiple system atrophy (2008)
- Cohen S, et al., CSF neurofilament light chain as biomarker in MSA (2024)
- Kiyoshita A, et al., Oligodendrocyte pathology in multiple system atrophy (2023)
- Fellner L, et al., Neuroinflammation in multiple system atrophy (2023)